Alternative Data for PTC Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 20 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 23,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 77 | Sign up | Sign up | Sign up |
| Facebook Followers | 6,964 | Sign up | Sign up | Sign up |
| Instagram Followers | 4,321 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,290 | Sign up | Sign up | Sign up |
| X Followers | 2,358 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 53 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,165 | Sign up | Sign up | Sign up |
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
| Price | $64.49 |
| Target Price | Sign up |
| Volume | 2,494,745 |
| Market Cap | $5.34B |
| Year Range | $43.3 - $86.25 |
| Dividend Yield | 0% |
| PE Ratio | 7.52 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $92February 22 - Benzinga |
|
PTC Therapeutics: Sephience As A Major Growth DriverFebruary 22 - SeekingAlpha |
|
 |
PTC Therapeutics price target raised by $4 at RBC Capital, here's whyFebruary 20 - Thefly.com |
|
PTC Therapeutics price target lowered by $7 at Wells Fargo, here's whyFebruary 20 - Thefly.com |
Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $86February 19 - Benzinga |
|
 |
PTC Therapeutics, Inc. (PTCT) Q4 2025 Earnings Call TranscriptFebruary 19 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 211M | 116M | 95M | 16M | 21M | 0.200 |
| Q2 '25 | 179M | 11M | 167M | -65M | -33M | -0.830 |
| Q1 '25 | 1.18B | 13M | 1.16B | 867M | 971M | 10.040 |
| Q4 '24 | 213M | 16M | 197M | -66M | -47M | -0.342 |
| Q3 '24 | 197M | 11M | 186M | -107M | -50M | -1.390 |
Insider Transactions View All
| Klein Matthew B. filed to sell 396,920 shares at $64.1. March 13 '26 |
| Okey Stephanie filed to sell 8,000 shares at $70. March 12 '26 |
| Okey Stephanie filed to sell 8,000 shares at $70. March 12 '26 |
| Almstead Neil Gregory filed to sell 2,737 shares at $63.4. March 9 '26 |
| Okey Stephanie filed to sell 8,000 shares at $63.4. March 9 '26 |
Similar companies
Read more about PTC Therapeutics (PTCT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - PTC Therapeutics
The Market Cap of PTC Therapeutics is $5.34B.
As of today, PTC Therapeutics' PE (Price to Earnings) ratio is 7.52.
Currently, the price of one share of PTC Therapeutics stock is $64.49.
The PTCT stock price chart above provides a comprehensive visual representation of PTC Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling PTC Therapeutics shares. Our platform offers an up-to-date PTCT stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, PTC Therapeutics (PTCT) does not offer dividends to its shareholders. Investors interested in PTC Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of PTC Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
